Alzamend Neuro Inc.

NASDAQ: ALZN · Real-Time Price · USD
2.38
-0.05 (-2.06%)
At close: Aug 15, 2025, 3:59 PM
2.41
1.26%
After-hours: Aug 15, 2025, 07:41 PM EDT

Alzamend Neuro Income Statement

Financials in USD. Fiscal year is May - April.
Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Apr 30, 2025 Apr 30, 2024 Apr 30, 2023 Apr 30, 2022 Apr 30, 2021
Revenue
n/a n/a n/a n/a n/a
Cost of Revenue
50.74K n/a n/a n/a n/a
Gross Profit
-50.74K -50.74K -23.07K n/a n/a
Operating Income
-4.5M -9.94M -14.87M -12.32M -4.95M
Interest Income
n/a n/a 7.70 46.52 1.71K
Pretax Income
-4.51M -9.95M -14.88M -12.36M -5.05M
Net Income
-4.51M -9.95M -14.88M -12.36M -5.05M
Selling & General & Admin
3.03M 3.48M 7.42M 7.12M 3.64M
Research & Development
1.41M 6.46M 7.45M 5.2M 1.31M
Other Expenses
n/a n/a n/a n/a n/a
Operating Expenses
4.45M 9.94M 14.87M 12.32M 4.95M
Interest Expense
18.03K 10.1K 7.7K 46.52K 158.8K
Selling & Marketing Expenses
n/a n/a 742.6K n/a n/a
Cost & Expenses
4.5M 9.94M 14.87M 12.32M 4.95M
Income Tax Expense
n/a n/a -145K 42.52K n/a
Shares Outstanding (Basic)
450.8K 3.38M 3.25M 2.96M 2.42M
Shares Outstanding (Diluted)
450.8K 3.38M 3.25M 2.97M 2.42M
EPS (Basic)
-11.32 -14.72 -2.25 -20.92 -0.89
EPS (Diluted)
-11.32 -14.7 -2.25 -2.1 -0.89
EBITDA
-4.45M -9.89M -14.85M -12.32M -4.95M
EBIT
-4.5M -9.94M -14.87M -12.32M -4.89M
Depreciation & Amortization
50.74K 50.74K 23.07K 3.55K 4.95M